MARKET

TECX

TECX

Tectonic Therapeutic Inc
NASDAQ
22.28
-0.43
-1.89%
After Hours: 22.27 -0.01 -0.04% 16:28 02/13 EST
OPEN
23.62
PREV CLOSE
22.71
HIGH
24.50
LOW
22.19
VOLUME
411.17K
TURNOVER
--
52 WEEK HIGH
40.58
52 WEEK LOW
13.70
MARKET CAP
417.00M
P/E (TTM)
-5.7903
1D
5D
1M
3M
1Y
5Y
1D
Here's How Much You Would Have Made Owning Tectonic Therapeutic Stock In The Last 5 Years
Benzinga · 2d ago
Insider Confidence Surges as Tectonic Therapeutic’s CEO Boosts Her Stake
TipRanks · 3d ago
CEO Alise Reicin Reports Acquisition of Tectonic Therapeutic Inc. Common Shares
Reuters · 3d ago
Top Executive Makes Bold Insider Move at Tectonic Therapeutic
TipRanks · 4d ago
Tectonic Therapeutic CFO Daniel Lochner Reports Acquisition of Common Shares
Reuters · 4d ago
Tectonic Therapeutic Hosts Virtual KOL Event Showcasing TX2100 for Hereditary Hemorrhagic Telangiectasia
Reuters · 4d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 5d ago
BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Datadog​, Ecolab
Reuters · 5d ago
More
About TECX
Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead asset, TX000045 (TX45), is a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). TX002100 (TX2100) is its second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).

Webull offers Tectonic Therapeutic Inc stock information, including NASDAQ: TECX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TECX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TECX stock methods without spending real money on the virtual paper trading platform.